Trial site
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
Santo André, 09060-870, BrazilNot linked to an institution yet
- 17running trials
- 6closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 321 trials
- Phase 22 trials
- Status
- Active, not recruiting11 trials
- Recruiting6 trials
- Completed4 trials
- Terminated2 trials
- Lead sponsor
- Daiichi Sankyo5 trials
- Pfizer3 trials
- Seagen, a wholly owned subsidiary of Pfizer3 trials
- Gilead Sciences2 trials
- Incyte Corporation2 trials
- and 7 more
Running trials
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· Phase 3· Daiichi Sankyo· Source
Contact: Principal Investigator
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· Phase 3· Daiichi Sankyo· Source
Contact: Study Coordinator
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· Phase 3· Gilead Sciences· Source
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743· Phase 3· Loxo Oncology, Inc.· Source
Contact: Debora Rodrigues Bonito (principal investigator)
Active, not recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· Phase 3· Gilead Sciences· Source
Active, not recruiting
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
NCT05270044· Phase 3· Pierre Fabre Medicament· Source
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· Phase 3· HUYABIO International, LLC.· Source
Active, not recruiting
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117· Phase 3· CanariaBio Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error